enGene Therapeutics (ENGN) vs vTv Therapeutics (VTVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
vTv Therapeutics (VTVT) has outperformed enGene Therapeutics (ENGN) over the past year, gaining 36.0% versus a loss of 76.0%. enGene Therapeutics is the larger company by market cap ($119.3 million vs $118.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENGN | VTVT |
|---|---|---|
| Share price | $1.78 | $30.08 |
| Market cap | $119.29M | $118.93M |
| 1-day change | +2.01% | -3.00% |
| YTD return | -80.29% | -24.78% |
| 1-year return | -75.98% | +35.99% |
| 5-year return | — | -48.84% |
| EPS (TTM) | $-2.07 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.25 | $44.00 |
| 52-week low | $1.40 | $19.50 |
| Distance from 52-week high | -85.47% | -31.64% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +84.83% | +81.88% |
| Average volume | 746.58K | 68.13K |
| Shares outstanding | 67.02M | 3.95M |
| Employees | 81 | 26 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTVT has outperformed ENGN by 112.0 percentage points over the past year.
About enGene Therapeutics
ENGN stock →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Healthcare · Biotechnology · 81 employees
About vTv Therapeutics
VTVT stock →vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Healthcare · Biotechnology · 26 employees
ENGN vs VTVT FAQ
Which is bigger, enGene Therapeutics or vTv Therapeutics?
enGene Therapeutics (ENGN) is larger, with a market capitalization of $119.29M compared with $118.93M for vTv Therapeutics (VTVT).
Which stock has performed better over the past year, ENGN or VTVT?
VTVT returned +35.99% over the past 12 months, compared with -75.98% for ENGN (price return, excluding dividends). Past performance does not predict future results.
Are enGene Therapeutics and vTv Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.